Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Adrenocortical carcinoma (ACC) is an aggressive cancer with poor response to chemotherapeutic and immunotherapeutic agents. About half of ACCs produce glucocorticoids (GC), and the presence of GC excess (hypercortisolism) is correlated with decreased survival in patients with ACC. The broad immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales: Habra, Mouhammed Amir, Hammer, Gary D, Kebebew, Electron, Worden, Francis P, Raj, Nitya, Hallanger-Johnson, Julie E, Grauer, Andreas, Moraitis, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089943/
http://dx.doi.org/10.1210/jendso/bvab048.188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089943/
http://dx.doi.org/10.1210/jendso/bvab048.188

Ejemplares similares